Efficacy News and Research

RSS

Study brings opportunities of personalised therapy for breast cancer a step closer

A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted therapies, and brings opportunities of truly personalised therapy for breast cancer a step closer, researchers said at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium.

2 May 2013

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).

2 May 2013

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.

2 May 2013

NeuroSigma receives Class 2 medical device license for Monarch eTNS System from Health Canada

NeuroSigma, Inc., a California-based medical device company, today announced that it has received a Class 2 medical device license for its Monarch eTNS (external trigeminal nerve stimulation) System from Health Canada.

2 May 2013

Study shows efficacy of PEGylated liposomal doxorubicin in intracranial model of breast cancer

Breast cancer brain metastases present a challenge to clinicians because there are few systemic therapies capable of crossing the blood-brain barrier to control the disease.

2 May 2013

New hope for patients with myotonic dystrophy

There's hope for patients with myotonic dystrophy. A new small molecule developed by researchers at the University of Illinois has been shown to break up the protein-RNA clusters that cause the disease in living human cells, an important first step toward developing a pharmaceutical treatment for the as-yet untreatable disease.

2 May 2013

Scientists pursue new therapies as H7N9 flu spreads in China

An experimental drug has shown promise in treating influenza, preventing lung injury and death from the virus in preclinical studies, according to University of Maryland School of Medicine researchers publishing in the journal Nature on May 1.

2 May 2013

New guidance on radioiodine therapy use after radiographic studies

Researchers have provided new evidence that could act as a guide for the use of radioiodine therapy after patients have undergone radiographic imaging studies that use iodine as a contrasting agent.

30 Apr 2013

Sufferers of gout and elevated uric acid levels have significantly increased death risks

A new study led by researchers at the Graduate Entry Medical School (GEMS), University of Limerick (UL) has found that people suffering from gout and elevated serum uric acid have significantly increased risks of death.

30 Apr 2013

FDA approves Octapharma USA's BLA for octaplex

The U.S. Food and Drug Administration has accepted Octapharma USA's Biological License Application for octaplex.

30 Apr 2013

IL-1 antagonist relieves dry eyes

Clinical trial results point to a role for interleukin-1 targeted agents for the treatment of dry eye disease associated with meibomian gland dysfunction.

29 Apr 2013

Delayed psychosis treatment harms chance of success

The longer patients with first-episode psychosis go untreated, the less likely they are to achieve remission within a year of starting treatment, report researchers.

29 Apr 2013

Absorption Pharmaceuticals to obtain patent for Promescent medication

Absorption Pharmaceuticals announced today that the U.S. Patent and Trademark Office has indicated that it will grant a patent related to the use of its topical medication, Promescent, for premature ejaculation.

29 Apr 2013

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus.

29 Apr 2013

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

Oramed Pharmaceuticals Inc., a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013.

29 Apr 2013

Opsona raises €33M in oversubscribed financing round

Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $ 43 million) in an oversubscribed Series C financing.

29 Apr 2013

Women eating more protein report weight loss success, researchers find

Atkins Diet, Zone Diet, South Beach Diet, etc., etc., etc. Chances are you have known someone who has tried a high protein diet. In fact, according to the International Food Information Council Foundation, 50% of consumers were interested in including more protein in their diets and 37% believed protein helps with weight loss.

29 Apr 2013

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases in Berlin, demonstrating solithromycin's potential to treat urogenital infections and combat challenging pathogens such as enterococci and Legionella pneumophila.

29 Apr 2013

MorphoSys initiates Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia patients

Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia.

29 Apr 2013

Geisinger and Bucknell celebrates opening of Autism and Developmental Medicine Center

Officials from Geisinger Health System and Bucknell University celebrated the grand opening of the Autism and Developmental Medicine Center, a national model for implementing guidelines for early diagnosis, medication management and treatment options for children with developmental disorders.

26 Apr 2013

Efficacy News and Research

Study brings opportunities of personalised therapy for breast cancer a step closer

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

NeuroSigma receives Class 2 medical device license for Monarch eTNS System from Health Canada

Study shows efficacy of PEGylated liposomal doxorubicin in intracranial model of breast cancer

New hope for patients with myotonic dystrophy

Scientists pursue new therapies as H7N9 flu spreads in China

New guidance on radioiodine therapy use after radiographic studies

Sufferers of gout and elevated uric acid levels have significantly increased death risks

FDA approves Octapharma USA's BLA for octaplex

IL-1 antagonist relieves dry eyes

Delayed psychosis treatment harms chance of success

Absorption Pharmaceuticals to obtain patent for Promescent medication

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

Opsona raises €33M in oversubscribed financing round

Women eating more protein report weight loss success, researchers find

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

MorphoSys initiates Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia patients

Geisinger and Bucknell celebrates opening of Autism and Developmental Medicine Center

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News